open access

Vol 54, No 4 (2020)
Invited editorial
Published online: 2020-08-31
Submitted: 2020-04-01
Accepted: 2020-04-02
Get Citation

Sexual dysfunction in Huntington’s Disease: what do we really know?

Philip W. Tipton
DOI: 10.5603/PJNNS.2020.0034
·
Pubmed: 32870497
·
Neurol Neurochir Pol 2020;54(4):291-293.

open access

Vol 54, No 4 (2020)
Invited editorial
Published online: 2020-08-31
Submitted: 2020-04-01
Accepted: 2020-04-02

Abstract

Introduction. In this edition, Szymuś et al. conducted a systematic review revealing sexual dysfunction to be more prevalent in patients with Huntington’s Disease compared to controls.

Clinical reflections. Sexual dysfunction in HD (SDHD) is common and significantly affects patient quality of life. Commonly used HD rating scales and treatment guidelines do not explicitly address SDHD, and research studies are limited by size and methodology.

Clinical implications. It is important that validated sexual dysfunction screening tools be utilised in clinical and research
settings.

Abstract

Introduction. In this edition, Szymuś et al. conducted a systematic review revealing sexual dysfunction to be more prevalent in patients with Huntington’s Disease compared to controls.

Clinical reflections. Sexual dysfunction in HD (SDHD) is common and significantly affects patient quality of life. Commonly used HD rating scales and treatment guidelines do not explicitly address SDHD, and research studies are limited by size and methodology.

Clinical implications. It is important that validated sexual dysfunction screening tools be utilised in clinical and research
settings.

Get Citation

Keywords

Huntington’s Disease, sexual dysfunction

About this article
Title

Sexual dysfunction in Huntington’s Disease: what do we really know?

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 54, No 4 (2020)

Pages

291-293

Published online

2020-08-31

DOI

10.5603/PJNNS.2020.0034

Pubmed

32870497

Bibliographic record

Neurol Neurochir Pol 2020;54(4):291-293.

Keywords

Huntington’s Disease
sexual dysfunction

Authors

Philip W. Tipton

References (24)
  1. Gusella JF, Wexler NS, Conneally PM, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature. 1983; 306(5940): 234–238.
  2. Kieburtz K, MacDonald M, Shih C, et al. Trinucleotide repeat length and progression of illness in Huntington's disease. J Med Genet. 1994; 31(11): 872–874.
  3. Roos RAC. Huntington's disease: a clinical review. Orphanet J Rare Dis. 2010; 5: 40.
  4. Pringsheim T, Wiltshire K, Day L, et al. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord. 2012; 27(9): 1083–1091.
  5. Glidden AM, Luebbe EA, Elson MJ, et al. Patient-reported impact of symptoms in Huntington disease: PRISM-HD. Neurology. 2020 [Epub ahead of print].
  6. Szymuś K, Bystrzyński A, Kwaśniak-Butowska M, et al. Sexual dysfunction in Huntington's Disease - a systematic review. Neurol Neurochir Pol. 2020 [Epub ahead of print].
  7. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). SpringerReference. .
  8. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord. 1996; 11(2): 136–142.
  9. Winder JY, Achterberg WP, Marinus J, et al. Assessment Scales for Patients with Advanced Huntington's Disease: Comparison of the UHDRS and UHDRS-FAP. Mov Disord Clin Pract. 2018; 5(5): 527–533.
  10. Youssov K, Dolbeau G, Maison P, et al. The unified Huntington's Disease Rating Scale for advanced patients: validation and follow-up study. Mov Disord. 2013; 28(14): 1995–2001.
  11. Armstrong MJ, Miyasaki JM. Evidence-Based Guideline: Pharmacologic Treatment of Chorea in Huntington Disease. 2012. www.neurology.org (27.03.2020).
  12. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997; 49(6): 822–830.
  13. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000; 26(2): 191–208.
  14. Simpson JA, Lovecky D, Kogan J, et al. Survey of the Huntington's Disease Patient and Caregiver Community Reveals Most Impactful Symptoms and Treatment Needs. J Huntingtons Dis. 2016; 5(4): 395–403.
  15. Kolenc M, Kobal J, Podnar S. Male sexual function in presymptomatic gene carriers and patients with Huntington's disease. J Neurol Sci. 2015; 359(1-2): 312–317.
  16. Kolenc M, Kobal J, Podnar S. Female Sexual Dysfunction in Presymptomatic Mutation Carriers and Patients with Huntington’s Disease. J Huntingtons Dis. 2017; 6(2): 105–113.
  17. Aldaz T, Nigro P, Sánchez-Gómez A, et al. Non-motor symptoms in Huntington's disease: a comparative study with Parkinson's disease. J Neurol. 2019; 266(6): 1340–1350.
  18. Aziz NA, Anguelova GV, Marinus J, et al. Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington's disease. Eur J Neurol. 2010; 17(8): 1068–1074.
  19. Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016; 17(18): 2461–2470.
  20. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007; 22(2): 193–197.
  21. Gregorian RS, Golden KA, Bahce A, et al. Antidepressant-induced sexual dysfunction. Ann Pharmacother. 2002; 36(10): 1577–1589.
  22. Mirek E, Filip M, Chwała W, et al. The influence of motor ability rehabilitation on temporal-spatial parameters of gait in Huntington's disease patients on the basis of a three-dimensional motion analysis system: An experimental trial. Neurol Neurochir Pol. 2018; 52(5): 575–580.
  23. Leavitt B, Kordasiewicz H, Schobel S. Huntingtin-Lowering Therapies for Huntington Disease. JAMA. 2020.
  24. Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Phase 1–2a IONIS-HTTRx Study Site Teams. Targeting Huntingtin Expression in Patients with Huntington's Disease. N Engl J Med. 2019; 380(24): 2307–2316.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl